- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04770779
Une étude évaluant l'efficacité et l'innocuité de Mitapivat chez des participants atteints d'alpha ou de bêta-thalassémie dépendante des transfusions (α- ou β-TDT) (ENERGIZE-T)
Une étude de phase 3, à double insu, randomisée, contrôlée par placebo et multicentrique évaluant l'efficacité et l'innocuité de Mitapivat chez des sujets atteints d'alpha ou de bêta-thalassémie dépendante des transfusions (ENERGIZE-T)
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The mitapivat group included 171 participants. The placebo group included 87 participants.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Berlin, Allemagne, 13353
- Charité - UB - CVK - Medizinische Klinik
-
Essen, Allemagne, 45122
- Universitätsklinikum Essen
-
Leipzig, Allemagne, 04103
- Universitätsklinikum Leipzig
-
-
-
-
-
Riyadh, Arabie Saoudite, 14611
- King Abdullah International Medical Research Center
-
Riyadh, Arabie Saoudite, 90210
- King Khalid University Hospital
-
-
-
-
-
Ribeirão Preto, Brésil, 14051-260
- Hospital Das Clínicas da Faculdade de Medicina de Ribeirão Preto - USP
-
São Paulo, Brésil, 04006-002
- GSH Banco de Sangue de São Paulo
-
-
-
-
-
Kyustendil, Bulgarie, 2500
- MHAT "Dr. Nikola Vasiliev" AD
-
Pleven, Bulgarie, 5800
- UMHAT "Dr. Georgi Stranski" Pleven
-
Plovdiv, Bulgarie, 4002
- UMHAT "Sveti Georgi" EAD
-
Sofia, Bulgarie, 1756
- SHATHD Sofia
-
Stara Zagora, Bulgarie, 6000
- UMHAT "Prof. Dr. Stoyan Kirkovich"
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- Foothills Medical Centre
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital, University Health Network
-
-
-
-
-
Hovedstaden, Danemark, 2100
- Rigshospitalet
-
-
-
-
-
Abu Dhabi, Emirats Arabes Unis
- Burjeel Medical City
-
-
-
-
-
Barcelona, Espagne, 08035
- Hospital Universitario Vall d'Hebron
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Murcia, Espagne, 30120
- Hospital Universitario Virgen Arrixaca
-
Seville, Espagne, 41013
- Hospital Universitario Virgen del Rocío
-
-
-
-
-
Créteil, France, 94010
- CHU Hôpital Henri Mondor
-
Lyon, France, 69003
- Hôpital Edouard Herriot, CHU de Lyon
-
Marseille, France, 13385
- CHU Hôpital de la Timone
-
Paris, France, 75015
- Hôpital Necker Enfants Malades
-
-
-
-
-
Achaia, Grèce, 26504
- University General Hospital of Patras
-
Athens, Grèce, 11527
- Children's Hospital Agia Sophia, National and Kapodistrian University of Athens Medical School
-
Athens, Grèce, 115 26
- Laiko General Hospital
-
Ioannina, Grèce, 455 00
- University Hospital of Ioannina
-
Thessaloniki, Grèce, 546 42
- Ippokrateio General Hospital
-
-
-
-
-
Brindisi, Italie, 72100
- Ospedale "A. Perrino" - Brindisi
-
Cagliari, Italie, 09121
- Ospedale Pediatrico Microcitemico
-
Ferrara, Italie, 44124
- Ospedale Sant'Anna
-
Genova, Italie, 16128
- Ente Ospedaliero Ospedali Galliera
-
Milan, Italie, 20122
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Modena, Italie, 41124
- A.O.U Di Modena
-
Naples, Italie, 80138
- AOU L. Vanvitelli Universita degli Studi della Campania Luigi Vanvitelli
-
Orbassano, Italie, 10043
- A.O.U. San Luigi Gonzaga
-
-
-
-
-
Beirut, Liban, 9999
- Chronic Care Center
-
-
-
-
-
Alor Star, Malaisie, 05460
- Hospital Sultanah Bahiyah
-
Johor Bahru, Malaisie, 80100
- Hospital Sultanah Aminah Johor Bahru
-
Kota Kinabalu, Malaisie, 88586
- Hospital Queen Elizabeth, Kota Kinabalu
-
Kuala Lumpur, Malaisie, 50300
- Hospital Tunku Azizah
-
Kuantan, Malaisie, 25100
- Hospital Tengku Ampuan Afzan
-
Kuching, Malaisie, 93586
- Hospital Umum Sarawak
-
Pandan Indah, Malaisie, 68000
- Hospital Ampang
-
Pulau Pinang, Malaisie, 10990
- Hospital Pulau Pinang
-
-
-
-
-
Amsterdam, Pays-Bas, 1105 AZ
- Amsterdam Universitair Medisch Centrum, Locatie AMC
-
Utrecht, Pays-Bas, 3584 CX
- Universitair Medisch Centrum Utrecht
-
Westzeedijk 353, Pays-Bas, 3015 AA
- Erasmus MC
-
-
-
-
-
London, Royaume-Uni, WC1E 6BT
- University College London
-
London, Royaume-Uni, W12 0HS
- Imperial College Healthcare NHS Trust - Hammersmith Hospital
-
-
-
-
-
Taipei, Taïwan, 100
- National Taiwan University Hospital
-
-
-
-
-
Bangkok, Thaïlande, 10400
- Phramongkutklao Hospital
-
Bangkok, Thaïlande, 10400
- Ramathibodi Hospital
-
Bangkok, Thaïlande, 10700
- Faculty of Medicine Siriraj Hospital
-
Chiang Mai, Thaïlande, 50200
- Maharaj Nakorn Chiang Mai Hospital
-
Khon Kaen, Thaïlande, 40000
- Srinagarind Hospital, Khon Kaen University
-
Mueang Phitsanulok, Thaïlande, 65000
- Naresuan University Hospital
-
Pathum Wan, Thaïlande
- King Chulalongkorn Memorial Hospital
-
-
-
-
-
Adana, Turquie (Türkiye), 1130
- Acibadem Adana Hospital
-
Antalya, Turquie (Türkiye), 07059
- Akdeniz University Faculty of Medicine
-
Balcalı, Turquie (Türkiye), 01330
- Çukurova University
-
Bornova, Turquie (Türkiye), 35040
- Ege University Faculty of Medicine
-
Fatih, Turquie (Türkiye), 34093
- Istanbul University Faculty of Medicine
-
Mersin, Turquie (Türkiye)
- Hacettepe University
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85016-7710
- Phoenix Children's Hospital
-
-
California
-
La Jolla, California, États-Unis, 92093
- San Diego Hospital, UC San Diego Health
-
Oakland, California, États-Unis, 94609-1809
- Children's Hospital Oakland
-
Palo Alto, California, États-Unis, 94304-1601
- Stanford Medicine
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Boston Children's Hospital
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201-2196
- Children's Hospital of Michigan
-
-
New York
-
New York, New York, États-Unis, 10065-4870
- Weill Cornell Medical Center
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710-3038
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Penn Medicine - University of Pennsylvania Health System
-
-
Washington
-
Seattle, Washington, États-Unis, 98101
- Seattle Cancer Care Alliance, University of Washington
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Greater than or equal to (≥)18 years of age at the time of providing informed consent;
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on deoxyribonucleic acid (DNA) analysis;
- Considered transfusion-dependent, defined as 6 to 20 red blood cells (RBC) units transfused and ≤6-week transfusion-free period during the 24-week period before randomization;
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization;
- Women of childbearing potential (WOCBP) must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle or agree to use two forms of contraception, one of which must be considered highly effective, from the time of providing informed consent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can be an acceptable barrier method;
- Written informed consent before any study-related procedures are conducted and willing to comply with all study procedures for the duration of the study.
Exclusion Criteria:
-
Pregnant, breastfeeding, or parturient;
-
Documented history of homozygous or heterozygous sickle hemoglobin (Hb S) or hemoglobin C (Hb C);
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation;
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization;
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization;
-
History of malignancy (active or treated) ≤5 years before providing informed consent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ;
-
History of active and/or uncontrolled cardiac or pulmonary disease ≤6 months before providing informed consent;
-
Hepatobiliary disorders;
-
Estimated glomerular filtration rate <45 milliliters per minute (mL/min)/1.73 meter (m)^2 by Chronic Kidney Disease Epidemiology Collaboration creatinine equation;
-
Nonfasting triglycerides >440 milligrams per deciliter (mg/dL) (5 millimoles per liter [mmol/L]);
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent;
-
Positive test for hepatitis C virus antibody (HCVAb) with evidence of active HCV infection, or positive test for hepatitis B surface antigen (HBsAg);
-
Positive test for human immunodeficiency virus (HIV)-1 antibody (Ab) or HIV-2 Ab;
-
History of major surgery (including splenectomy) ≤6 months before providing informed consent and/or a major surgical procedure planned during the study;
-
Current enrollment or past participation (≤12 weeks before administration of the first dose of study drug or a timeframe equivalent to 5 half-lives of the investigational study drug, whichever is longer) in any other clinical study involving an investigational treatment or device;
-
Receiving strong CYP3A4/5 inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer); or strong CYP3A4 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization;
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed. The testosterone dose and preparation must be stable for ≥12 weeks before randomization;
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, and magnesium stearate, Opadry® II Blue [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and Federal Food, Drug, and Cosmetic (FD&C) Blue #2]);
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Mitapivat
Participants randomized to receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 48 weeks in the double-blind (DB) period and for up to 5 years in the open label extension (OLE) period. |
Tablets
Autres noms:
|
|
Comparateur placebo: Placebo
Participants randomized to receive placebo matching mitapivat, orally, BID for 48 weeks in the DB period followed by mitapivat 100 mg, orally, BID for up to 5 years in the OLE period. |
Tablets
Autres noms:
Tablets |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)
Délai: Double-blind Period: Baseline through Week 48
|
TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders. |
Double-blind Period: Baseline through Week 48
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Période en double aveugle: concentrations plasmatiques de mitapivat
Délai: Période en double aveugle: pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
Période en double aveugle: pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
|
|
Période en double aveugle: concentration plasmatique observée maximale (CMAX) de mitapivat
Délai: Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
|
|
Période en double aveugle: temps pour atteindre la concentration plasmatique observée maximale (TMAX) de mitapivat
Délai: Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
|
|
Période en double aveugle: temps de dernière concentration quantifiable (TLAST) de mitapivat
Délai: Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
Période en double aveugle: pré-dose, 0,5, 1, 3, 5, 7 heures après la semaine 36
|
|
|
Période en double aveugle: concentration sanguine de l'adénosine triphosphate (ATP)
Délai: Période en double aveugle: pré-dose au jour 1; pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
Période en double aveugle: pré-dose au jour 1; pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
|
|
Période en double aveugle: concentration sanguine de 2,3 - diphosphoglycérate (2,3-DPG)
Délai: Période en double aveugle: pré-dose au jour 1; pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
Période en double aveugle: pré-dose au jour 1; pré-dose à la semaine 12; pré-dose à la semaine 24; Pré-dose, 0,5, 1, 3, 5, 7 heures après la dose à la semaine 36
|
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR2
Délai: Double-blind period: Baseline through Week 48
|
TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders. |
Double-blind period: Baseline through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR3
Délai: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved TRR4
Délai: Double-blind period: Baseline up to Week 13 through Week 48
|
TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders. |
Double-blind period: Baseline up to Week 13 through Week 48
|
|
Double-blind Period: Percent Change From Baseline in Transfused RBC Units
Délai: Double-blind Period: Baseline, Week 13 through Week 48
|
Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed. |
Double-blind Period: Baseline, Week 13 through Week 48
|
|
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence
Délai: Double-blind Period: Baseline through Week 48
|
Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Iron Levels
Délai: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on Iron levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Serum Ferritin Levels
Délai: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on serum ferritin levels. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Total Iron Binding Capacity
Délai: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels
Délai: Double-blind Period: Baseline through Week 48
|
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity. |
Double-blind Period: Baseline through Week 48
|
|
Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
Délai: Double-blind Period: From first dose of study drug up to week 48
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Double-blind Period: From first dose of study drug up to week 48
|
|
Open-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3
Délai: Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious & non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE. |
Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
|
|
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Délai: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
|
|
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Délai: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses. |
Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Medical Affairs, Agios Pharmaceuticals, Inc.
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AG348-C-018
- 2021-000212-34 (Numéro EudraCT)
- 2024-512747-23-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .